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Cell cycleThe human papillomavirus 16 E2 protein regulates transcription from, and replication of, the viral genome
and is also required for segregation of the viral genome via interaction with mitotic bodies. To regulate DNA
replication E2 interacts with sequences around the origin of replication and recruits the viral helicase E1 via a
protein-protein interaction, which then initiates viral genome replication. The replication role of E2 must
originally function in a host cell S phase. In this report, we demonstrate that E2 is stabilised in the S phase of
the cell cycle and that this stabilisation is accompanied by an increase in phosphorylation of the protein. This
increased phosphorylation and stability are likely required for optimum viral DNA replication and therefore
identiﬁcation of the enzymes involved in regulating these properties of E2 will provide targets for
therapeutic intervention in the viral life cycle. Preliminary studies have identiﬁed E2 as a Cdk2 substrate
demonstrating this enzyme as a candidate kinase for mediating the in vivo phosphorylation of HPV16 E2.
© 2009 Elsevier Inc. All rights reserved.Introduction
The papillomavirus E2 protein has a modular structure; a carboxyl
terminal dimerisation and DNA binding domain, a middle hinge
region and an amino terminal transcriptional activation/E1 interact-
ing domain (Steger et al., 1996). HPV E2 dimerises and binds to four
12 bp palindromic target sequences within the long control region
(LCR) of the virus; the organisation of these target sequences is
conserved amongst all HPV. Following interactionwith the LCR, the E2
protein can regulate transcription from the adjacent E6 promoter
(Steger and Corbach, 1997). Most reports describe repression of HPV
transcription by E2, but studies in primary cells demonstrate that low
E2 levels activate transcription while increased levels result in
transcriptional repression (Bouvard et al., 1994). Three of the E2
target sequences in the LCR surround the viral origin of DNA
replication (ori). Following binding to their target sites at the ori, a
physical interaction between the amino terminal domain of E2 and
the viral DNA replication factor E1 results in recruitment of E1 to the
origin of replication (Benson and Howley, 1995; Mohr et al., 1990). E1
then interacts with the AT rich ori and forms a di-hexameric complex
with helicase activity that unwinds the double stranded DNA viral
genome and recruits factors to initiate DNA replication (Hu et al.,
2006; Loo and Melendy, 2004; Masterson et al., 1998; Schuck and
Stenlund, 2005). Another crucial role for E2 in the viral life cycle is to
mediate viral genome segregation during cell division. The E2 protein
is loaded onto mitotic chromatin by the cellular protein ChlR1 (Parish
et al., 2006) and interaction with the cellular factor Brd4, which is).
ll rights reserved.associated with mitotic chromatin, regulates viral genome partition
for some E2 proteins; the amino terminal domain of E2 interacts with
the mitotic chromatin via Brd4 while the carboxyl terminal domain
interacts with the viral genome (You et al., 2004). Brd4 is not required
for the genome segregation function of all E2 proteins (McPhillips et
al., 2006) and E2 can interact with alternative mitotic bodies and
proteins including tubulins and TopBP1 (Boner et al., 2002; Donaldson
et al., 2007; Van Tine et al., 2004).
All of these functions of E2 are required for a productive viral life
cycle and therefore their disruption would be anti-viral. One way to
regulate the E2 protein and disrupt its function is to target the stability
of the protein itself. For BPV1 E2, protein stability is mediated via
phosphorylation in the hinge region of the protein (Penrose and
McBride, 2000), while for HPV18 E2, a sequence in the amino terminal
domain of the protein is essential for regulating protein turnover
(Bellanger et al., 2001). Previous work from our lab has established
that the HPV16 E2 protein half life is 45 min, which is reduced
following UVB irradiation although the phosphorylation status of this
protein has not been investigated (Taylor et al., 2003). In this report,
we have investigated the protein turnover of HPV16 E2 during the cell
cycle with particular emphasis on the S phase. Previously, we have
shown that U2OS cells can stably express the HPV16 E2 protein (from
now on denoted E2) (Taylor et al., 2003) and also support E1-E2
mediated DNA replication (Boner et al., 2002). This represents the
only known system in which the cell cycle control of HPV16 E2
expression can be studied. The U2OS model system, that supports E2
mediated DNA replication, was therefore used to investigate the cell
cycle control of E2 protein levels. There is a peak of E2 protein in S
phase mediated by increased protein stability. E2 is phosphorylated
throughout the cell cycle and results suggest that phosphorylation is
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in S phase likely contribute to the replication function of the protein,
therefore identiﬁcation of the enzymes responsible will reveal anti-
viral therapeutic targets. Preliminary results suggest that Cdk2may be
mediating this phosphorylation.
Results and discussion
E2 protein levels peak in S phase
All experiments were performed using the previously described
U2OS B3 clone that expresses HPV16 E2 (Taylor et al., 2003), although
some were repeated in other clones with similar E2 levels, giving
identical results. Throughout this report, these will be referred to as
U2OS-E2 and control cells U2OS-Vec, the latter were prepared at the
same time as the E2 line with a vector not encoding E2. In order to
synchronise the cells, they were treated with the DNA polymerase
inhibitor aphidicolin (5 μg/ml) for 16 h. This treatment arrests the
cells at the G1-S phase transition of the cell cycle (called G1 from now
on). The drug was then removed, allowing for cell cycle progression,
and cells were harvested at different time points and protein extracts
prepared. E2 protein levels were investigated using western blotting.
Cells arrested in G1 showed reduced levels of the E2 protein compared
to cycling cells (Fig. 1A). Following release from aphidicolin, E2 levels
were increased at 4 h, after which they were reduced by 8 h before
returning to basal levels by 12 h. This experiment was repeated
several timeswith very similar results. The blots were quantitated and
the results are shown in Fig. 1B where it is evident that there is anFig. 1. E2 protein levels peak in S phase. (A) E2-expressing cells were treated with 5 μg/ml a
treated cells. E2 and γ-tubulin were detected with western blot using the TVG261 and GTU8
shown normalised to γ-tubulin. (C) Progression of the cell cycle in E2-expressing and non-increase of the E2 protein levels 4 h following aphidicolin release. To
conﬁrm that the cells at 4 and 8 h time points represented S phase
populations, ﬂow cytometry was carried out and the results shown in
Fig. 1C; this experiment was repeated another two times with
essentially the same results. Substantial numbers of the cells are in S
phase at the 4 and 8 h time points and the E2-expressing cells seem to
progress into and through S phase at a slightly slower rate than
control cells. However, this slight lack of cell cycle co-ordination could
not explain the differences in E2 protein levels observed in Fig. 1A and
cell growth studies demonstrate that E2-expressing cells grow at the
same rate as control cells (not shown). It should be noted that at the 4
h time point the S phase is not so pronounced, but as there is a G2 peak
it demonstrates the cells are progressing through the cell cycle and
although the G1 peak is large, it is likely that a lot of these cells have
entered S phase.
To conﬁrm that the E2 protein increase was a post-transcriptional
event, RNA levels were measured throughout the cell cycle (Fig. 2A).
Although there is a small increase in E2 RNA levels at 4 h, it was not
reﬂective of the increase in protein levels, nor was it sustained to the
8 h time point. Immunoﬂuorescence studies also demonstrated an
increased E2 protein level during S phase (Fig. 2B). This technique
detects the total amount of the E2 protein in the cell, ruling out
differences in solubility of the E2 protein that could vary over the cell
cycle. While not quantitative, it is clear that there is a peak in the E2
signal detected by immunoﬂuoresence at the 4 h time point. Taken
together, these results demonstrate that the E2 protein levels are
increased in the S phase of the cell cycle, and that this increase is
regulated at a translational or post-translational level.phidicolin for 16 h, washed and harvested at time points indicated. “-” represents non-
8 monoclonal antibodies, respectively. (B) Blots in A were quantiﬁed and E2 levels are
expressing cells was veriﬁed by propidium iodide staining and ﬂow cytometry.
Fig. 2. Increase in S phase E2 is not due to RNA levels or E2 solubility. (A) E2 RNA levels were detected using real-time PCR (probe and primer sets are available upon request). The
graph represents 3 experiments with results normalised to β-actin. (B) Cells grown on coverslips were ﬁxed and stained with the TVG261 monoclonal E2 antibody and anti-mouse-
FITC conjugated antibody. Vec represents control cells stably transfected with an empty vector not expressing E2.
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To investigate whether the increased E2 protein level is due to
increased stability, E2-expressing cells were synchronised in G1 and S
phase (0 and 4 h time point respectively) and thereafter treated with
the protein synthesis inhibitor cycloheximide for indicated timeFig. 3. The E2 protein is more stable in S phase and has increased afﬁnity for chromatin. (A
10 μg/ml cycloheximide for indicated time periods. E2 and γ-tubulin were detected using w
release. (B) Blots were quantiﬁed and E2 levels relative to pre-cycloheximide treatment we
experiments. (C) Proteins from synchronised E2-expressing cells were serially extracted u
(Donaldson et al., 2007) and E2 detected using western blot. “0” represents aphidicolin arr
treated cells. (D) Blots in A were quantiﬁed and E2 levels in each salt fraction were plottedperiods. It is clear that there is an increased E2 stability in the S phase
sample (Fig. 3A, lower panel). The experiment shown is an example of
at least three independent experiments and the quantitated results,
with associated standard errors, are shown in Fig. 3B. In G1 cells, the
half life of E2 was 45 min, which was similar to that of a non-
synchronised population (Taylor et al., 2003, and data not shown).) E2-expressing cells were synchronised with aphidicolin as in Fig. 1 and treated with
estern blot. “0” represents aphidicolin arrested cells, “4” represents cells 4 h following
re plotted. The graph represents the standard error of the mean of three independent
sing NP40 lysis buffer with salt concentrations ranging from 0.1 to 1 M as described
ested cells, “4” and “8” represent cells 4 and 8 h following release; “–” represents non-
as a percentage of the E2 total for each time point.
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approximately 90 min. This indicates that the increase in E2 protein
levels during S phase was mediated by increased protein stability.
Previous studies have shown that E2 with a higher afﬁnity for
chromatin is more stable (Donaldson et al., 2007). It was therefore
possible that the enhanced E2 levels detected in S phase were due to
elevated levels of soluble E2 extracted from the chromatin. To test
this, E2was serially extracted from the nuclear pellets of synchronised
cells using increasing concentration of salt (Fig. 3C). In the S phase
samples (4 and 8 h), E2 showed increased afﬁnity for chromatin,
indicated by the increased amount of extracted protein in the high salt
fractions. Blots were quantiﬁed and graphically represented in Fig. 3D
where the increase in the percentage of E2 in the higher salt fractions
at the later time points was evident. Looking cumulatively at the level
of E2 protein in each of the salt extracts and the cell pellet, it is again
clear that the total level of E2 protein is elevated in the S phase
extracts. This is in agreement with the results shown in Figs. 1 and 2
where increased E2 levels in westerns and immunoﬂuorescence,
respectively, are detected.
The levels of E2 phosphorylated protein increase in S phase
In Fig. 1A at the 4 and 8 h time points, there is evidence for a sub-
population of E2 protein with slower mobility that could represent
modiﬁed versions of the protein. BPV1 E2 has two major phosphor-
ylation sites that regulate turnover of the protein; targeting of residue
301 by casein kinase II results in a conformational change resulting in
protein degradation (Penrose et al., 2004). These residues are not
conserved in the high risk HPV E2 proteins nor is the mechanism of
protein turnover. The amino terminal domain of HPV18 E2 is required
for proteasome mediated degradation (Bellanger et al., 2001),
although the signals that trigger this degradation remain unknown.
There have been no reports to date investigating the phosphorylation
status of the HPV16 E2 protein throughout the cell cycle and how this
might relate to the control of protein turnover. As phosphorylation
clearly regulates the turnover of other E2 proteins, the phosphory-
lation status of E2 in untreated, G1 and S phase cells was investigatedFig. 4. E2 protein is phosphorylated in vivo. (A) Schematic diagram showing phosphopro
manufacturer's instructions. (B) The lysates were loaded onto columns, eluted, TCA precipita
cells 4 h following release, “–” represents non-treated cells. “E” represents the eluate from t
the kit as well as samples lysed in our standard buffer (Figs. 1–3) are shown for compar
quantiﬁed and the amount of E2 in the eluted fractions relative to untreated cells (−) wa
experiments. (D) Input (I), eluate (E) and ﬂowthrough (F) of one of the experiments summar
ASF to conﬁrm that phosphorylated proteins were sticking to the columns.using the Qiagen Phosphoprotein Puriﬁcation Kit. Protein extracts
from E2-expressing cells were prepared from untreated and aphidi-
colin arrested cells as well as cells 4 h following release from
aphidicolin using a lysis buffer provided in the kit. These lysates were
then processed and analysed as described in Fig. 4A. Input levels of E2
were determined prior to loading onto the phospho-protein puriﬁ-
cation column using western blotting as shown in Fig. 4B. With the
Qiagen buffer, the increase in E2 levels in S phase is not as obvious as
in Fig. 1 and therefore identical cell samples from the same
experiment were prepared using NP40 buffer (used in the experi-
ments shown in Fig. 1) and blotted for E2 levels. This is shown in Fig.
4B where it is clear that there is the previously observed peak in S
phase levels of the E2 protein γ-tubulin controls to conﬁrm equal
loading. The protein lysates prepared using the Qiagen buffer were
then added to phosphor-afﬁnity columns and fractions collected as
ﬂow through (F), or following elution (E). Phosphorylated E2 could be
detected in G1 and S phase eluates, and also in untreated (−) cells
(Fig. 4B). There was more E2 in the eluate of the S phase sample
relative to the input sample suggesting increased phosphorylation of
E2 in S phase. This increase was robust and reproducible in several
experiments, and therefore, densitometry was carried out on three
independent experiments and the levels of E2 in the eluate are shown
graphically in Fig. 4C with standard error bars. TCA precipitation was
used to reduce the volume of the ﬂowthrough protein sample before
western blotting and this resulted in variable detection of E2 due to
difﬁculties in reproducible precipitation of the protein samples. To
conﬁrm that the phosphor-protein columns were operating success-
fully, a known phosphorylated cellular protein, SF2/ASF (Hanamura et
al., 1998)was included as a control and the results are shown in Fig. 4D
for one of the experiments summarised in Fig. 4C (this was done with
all experiments and identical results obtained). Clearly, the SF2/ASF is
retained on the phosphor-column as it is detected in the eluted
fraction. This conﬁrms the ability of the columns to bind known
phosphor-proteins. The increased E2 phosphorylation could explain
the enhancement of E2 protein stability as modiﬁcation could either
directly regulate E2 turnover or be responsible for the association of E2
with additional cellular complexes inwhich the protein ismore stable.tein puriﬁcation using the Phosphoprotein Puriﬁcation Kit (Qiagen) according to the
ted and western blotted for E2. “0” represents aphidicolin arrested cells, “4” represents
he phosphoprotein afﬁnity column; “F” represents the ﬂow through. Input lysates from
ison (both extracts prepared from the same treated cell population). (C) Bands were
s plotted. The graph represents the mean and standard error of the mean from three
ised in panel C were probed with an antibody against the known phosphor-protein SF2/
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proteins such as Cdc45 onto origins to initiate DNA replication and
phosphorylation of the viral E1 protein by Cdk2 is required for the
activation of HPV DNA replication (Ma et al., 1999). It was therefore
possible that Cdk2 is involved in the phosphorylation of the E2 protein
during S phase as E2 has a Cdk consensus sequence (TP) in the DNA
binding domain at amino acids 286–287 (Fig. 5A). This was
investigated in vitro using GST fusion proteins (Fig. 5B) and puriﬁed
recombinant Cdk2. Fig. 5C demonstrates that E2 was a substrate of
Cdk2 in vitro and that mutation of T286 to alanine resulted in a
signiﬁcant reduction in E2 phosphorylation. However, a residual level
of phosphorylation remained suggesting an additional non-consensus
Cdk2 target within E2 and this was supported by an amino terminal
deletion mutant lacking S286 that was still phosphorylated. This
indicates that there are at least two Cdk2 target sequences in E2. A
T286A mutant of E2 expressed in vivo had no alteration in S phase
accumulation or protein stability indicating that this residue by itself
is not responsible for regulating E2 stability.
The results presented in this report demonstrate that HPV16 E2 is
stabilised in the S phase of the cell cycle, that there is increased
phosphorylation of the protein in S phase, and that it is a Cdk2
substrate, at least in vitro. Clearly, all of these aspects may combine to
explain our observations; increased phosphorylation of E2 may
stabilise the E2 protein in S phase. Phosphorylation of the HPV E1
protein regulates the nuclear shuttling of this protein (Yu et al., 2007)
althoughwith E2 this does not seem to be the case as it is not detected
in the cytoplasm at any point in the cell cycle (Fig. 2B). Upon entry into
S phase, several proteins involved in the initiation of DNA replication
are phosphorylated by kinases such as Cdk2 and these modiﬁcations
are essential for the replication function (Aleem et al., 2004). Elevated
levels of Cdk2 activity in early S phase promote loading of proteins
such as Cdc45 onto origins to initiate DNA replication and phosphor-
ylation of the viral E1 protein by Cdk2 is required for the activation of
HPVDNA replication (Ma et al., 1999).We have identiﬁed E2 as a Cdk2
substrate in vitro and mutation of a Cdk2 target sequence resulted in
reduction of Cdk2 phosphorylation, but in vivo, mutation of the target
residue (T286A) did not alter E2 stability (not shown).
It is also possible that other modiﬁcations of E2 play a role in
regulating protein stability and function throughout the cell cycle. For
example, recent studies demonstrate that cellular sumoylation levelsFig. 5. Cdk2 phosphorylates E2 in vitro. (A) There is a consensus Cdk2 phosphorylation site at
run on an SDS-PAGE gel and stained with Coomassie Brilliant Blue. (C) In vitro Cdk2 kinase a
was included as a positive control as it is a known target protein for Cdk2 mediated phospcan inﬂuence E2 stability (Wu et al., 2009) and this could alter
throughout the cell cycle. Alternatively, additional phosphorylation
events may contribute to the regulation of E2 stability. Future work
will focus on identifying the modiﬁed residues on E2 and how they
regulate stability. This will allow the identiﬁcation of the enzyme
responsible for modiﬁcation and this will represent a target for
regulating E2 protein levels and therefore target HPV infections.
Materials and methods
Cell culture
E2-expressing U2OS cells (clone B3) and cells containing the
empty vector (Taylor et al., 2003) were grown in DMEM+GlutaMAX
containing 10% FCS. For G1 arrest, cells were treated with 5 μg/ml
Aphidicolin for at least 16 h. Cells were then washed to allow
progression of the cell cycle and harvested at indicated time points. To
determine protein half life, cells were treated with 10 μg/ml of
cycloheximide for indicated time periods.
Flow cytometry
Cells were harvested by trypsinisation followed by 2 washes with
PBS. Cell pellets were resuspended in 500 μl of PBS, placed on ice and
ﬁxed with 4.5 ml of ice cold 70% ethanol added drop wise over a vortex
at low speed. The cells were incubated on ice for 30 min, or if not
required immediately, stored at−20 °C. ForDNAanalysis, the cellswere
stained with Propidium Iodide. The cells were washed twice with PBS
and resuspended in 500 μl of PBSwith 2 μl of Propidium Iodide (10mg/
ml) and 1 μl of Ribonuclease A. The stainingwas carried out for at least 3
h at 4 °C. The samples were analysed using the EXPO32ADCXL4 Colour
program on a Beckman Coulter Epics XL-MCL machine.
IF staining
Cells grown on coverslips were ﬁxed in 4% formaldehyde for 10
min at 37 °C and permeabilised using 0.5% NP40, 0.3 mM sucrose in
PBS. Slides were blocked in 10% FCS in PBS+0.1% Tween. E2 was
detected using the TVG261 mouse monoclonal E2 antibody at 1:5
dilution and anti-mouse-FITC conjugated antibody (Sigma) at 1:1000residue threonine 286 as shown. (B) GST fusion proteins were prepared from E. coli and
ssays were carried out with recombinant Cdk2 and the GST fusion proteins; histone H1
horylation. The arrow shows the autophosphorylation of the Cdk2 kinase.
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1% FCS. Slides were mounted using Vectashield containing DAPI. Cells
were examined with a Leica TCS SP2 confocal microscope and the
Leica Confocal Software.
Western blot
Cells were lysed in NP40 lysis buffer (50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 0.5% NP40). For salt fractionation, cell pellets were
serially extracted in the same buffer using salt concentrations ranging
from 0.1 to 1 M. Protein concentration was determined using the BCA
assay (Sigma). Equal amounts (30–50 μg) of total protein were loaded
on a 4–12% gradient gel (Invitrogen) and run for 1 h. Proteins were
transferred to a nitrocellulose membrane with Invitrogen's iBlot
system. Membrane was blocked in 5% milk in PBS+0.05% Tween. E2
and γ-tubulin were detected using the TVG261 (Hibma et al., 1995)
and GTU88 monoclonal antibodies, respectively. Western blots were
scanned and quantiﬁed using the Image J software. The antibody Mab
96 against SF2/ASF was a gift from Dr. Javier Caceres, Edinburgh.
Real-time qPCR
RNA was prepared using the Trizol reagent (Invitrogen) according
to themanufacturer's instructions. cDNAwas synthesised from 1–2 μg
of total RNA using Superscript II (Invitrogen) and an oligo-dT primer.
E2 and β-actin RNA levels were detected using real-time qPCR (probe
and primer sets are available upon request).
Phosphoprotein puriﬁcation
Phosphoprotein puriﬁcation from synchronised cells was carried
out using the Phosphoprotein Puriﬁcation Kit (Qiagen) according to
the manufacturer's instructions. The change in E2 levels was veriﬁed
in samples from the same treated cell population prepared with
buffer provided in the kit as well as NP40 lysis buffer. The lysates
were loaded onto columns, eluted, TCA precipitated and western
blotted for E2.
Site-directed mutagenesis
Mutation of the E2 sequence encoding threonine 286 to alanine
was carried out using the KOD Hot Start DNA polymerase (Novagen)
according to Novagen's protocol for site-directed mutagenesis.
GST protein expression
To purify GST proteins, bacteria induced with 2 mM IPTG were
lysed in NETN buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA,
0.5% NP-40) and sonicated in an ice water bath for 12 × 30 s. The
cleared lysate was incubated with Glutathione sepharose (GE
Healthcare) for 1.5 h and the beads were washed ﬁve times in
NETN buffer. The amount of GST fusion protein was estimated on a
SDS-PAGE gel stained with Coomassie Brilliant Blue.
Cdk2 phosphorylation assays
Fifty nanograms of recombinant puriﬁed human CDK2/CyclinA
(Invitrogen) and 2 μg of GST protein or histones (Sigma) were
preincubated at 30 °C for 10 min. Kinase buffer (20 mM Tris pH 7.5,
5 mMMgCl2, 100 mM ATP, 0.5 μCi 32P-γATP) was added and samples
were incubated for an additional 10min at 30 °C. Sampleswere run on
an SDS-PAGE gel and phosphorylated proteins were identiﬁed using a
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